N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth...

Area of Science:

• Neonatal Medicine
• Respiratory Physiology
• Pharmacology

Background:

• Bronchopulmonary dysplasia (BPD) in preterm infants is linked to oxygen toxicity.
• Glutathione (GSH) is a key lung antioxidant, and N-acetylcysteine (NAC) may enhance its function.
• Investigating NAC's potential to mitigate lung injury in vulnerable newborns.

Purpose of the Study:

• To determine if prophylactic intravenous N-acetylcysteine (NAC) treatment improves neonatal lung function in very preterm infants.
• To assess NAC's impact on lung injury as measured by respiratory mechanics and gas exchange.

Main Methods:

• A multi-center Nordic controlled trial involving prophylactic intravenous NAC (16-32 mg/kg/day for 6 days) in infants with birth weights 500-999 g.
• Lung function tests, including compliance, resistance, functional residual capacity, and gas mixing efficiency, were performed before NICU discharge.
• 33 infants (18 NAC, 15 placebo) with a median gestational age of 25 weeks were analyzed.

Main Results:

• No significant differences in lung function measurements were observed between the NAC-treated group and the placebo group.
• Key respiratory parameters such as compliance, resistance, and gas mixing efficiency showed no improvement with NAC treatment.
• Infant characteristics, including gestational age and birth weight, were comparable between the groups.

Conclusions:

• Prophylactic NAC treatment during the first week of life does not enhance lung function in extremely low birth weight infants.
• The findings suggest NAC is not effective in improving neonatal lung function in this high-risk population.
• Further research may be needed to explore alternative or adjunctive therapies for preventing BPD.